Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

Antimicrobial Activities and Postantibiotic Effects of Clarithromycin, 14-Hydroxy-Clarithromycin, and Azithromycin in Epithelial Cell Lining Fluid against Clinical Isolates ofHaemophilus influenzae and Streptococcus pneumoniae

Kimberly L. Bergman, Keith M. Olsen, Tom E. Peddicord, Paul D. Fey, Mark E. Rupp
Kimberly L. Bergman
Departments of Pharmacy Practice and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith M. Olsen
Departments of Pharmacy Practice and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tom E. Peddicord
Departments of Pharmacy Practice and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul D. Fey
Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska 68198
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark E. Rupp
Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska 68198
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.43.5.1291
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

The antimicrobial activity of concentrations of selected macrolides found in epithelial cell lining fluid was investigated. Clarithromycin demonstrated greater potency and a significantly longer postantibiotic effect (PAE) than azithromycin againstStreptococcus pneumoniae. Azithromycin displayed greater potency, faster killing, and a longer PAE than clarithromycin againstHaemophilus influenzae. Drug concentrations in epithelial cell lining fluid similar to those found in tissue did not improve the synergistic potential of 14-hydroxy-clarithromycin and indicate that a maximal PAE may exist despite increasing concentrations of drug.

The bacterial pathogens most commonly responsible for community-acquired pneumonia (CAP) infections include Streptococcus pneumoniae andHaemophilus influenzae (2, 10). Institution of appropriate empiric antimicrobial therapy is the cornerstone of treatment for CAP (1). Newer macrolides, specifically clarithromycin and azithromycin, are used in the treatment of CAP based on enhanced antibacterial spectra and unique pharmacokinetic properties in comparison to those of erythromycin. Clarithromycin possesses increased activity againstH. influenzae and most streptococcal species (11, 17), and its active metabolite, 14-hydroxy-clarithromycin, has demonstrated greater activity against H. influenzae and additive or synergistic properties when combined with clarithromycin (9, 16, 18). The azalide antibiotic azithromycin exhibits two to four times the bactericidal potency of erythromycin against H. influenzae (5, 17, 21, 26).

In addition to enhanced spectra, clarithromycin and azithromycin display unique pulmonary tissue pharmacokinetics. Clarithromycin concentrations in lung epithelial cell lining fluid (ELF), a proposed site of infection in CAP (4), have ranged from 10 to 30 times higher than those in serum (12, 25, 27). 14-Hydroxy-clarithromycin also achieves concentrations in ELF that are superior to those in serum (6, 12, 27). Azithromycin consistently demonstrates high and sustained concentrations in lung ELF and alveolar macrophages (13, 24, 27). Data illustrating the effect of these antibiotic concentrations at the site of infection on bacterial growth is limited. Our purpose was to define the antimicrobial effects of concentrations of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in ELF on in vitro growth characteristics ofH. influenzae and S. pneumoniae, as evidenced by MICs and MBCs, time-kill curves, and postantibiotic effects (PAEs).

One reference strain and four clinical strains each ofS. pneumoniae and H. influenzaewere studied. Antimicrobial agents were obtained from their respective manufacturers. S. pneumoniae was grown in cation-adjusted Mueller-Hinton broth (Difco, Detroit, Mich.) supplemented with 2% lysed horse blood (Colorado Serum Co., Denver), and viability counts were performed with 5% sheep blood agar plates (Remel, Lenexa, Kans.). H. influenzae was grown in Haemophilus test medium (Remel), and viability counts were performed with chocolate agar plates (Remel).

The MICs and MBCs of clarithromycin and azithromycin were determined by the standard broth microdilution method (20, 22). Viability counts were determined from plates yielding 30 to 300 colonies. Time-kill experiments were performed with clarithromycin, azithromycin, 14-hydroxy-clarithromycin, and a combination of clarithromycin and 14-hydroxy-clarithromycin at the following concentrations found in lung ELF: clarithromycin, 30 μg/ml; azithromycin, 3 μg/ml; and 14-hydroxy-clarithromycin, 2 μg/ml (3, 7, 19, 24, 27). An initial log-phase inoculum of 6 × 105 CFU/ml was added, and the suspensions were incubated aerobically at 37°C with shaking at 100 rpm. Viable-cell counts were performed at 0, 1, 3, 6, and 24 h with plates incubated in 5% CO2.

In vitro determination of PAE at the aforementioned concentrations in lung ELF was performed by the broth technique (8). A final log-phase inoculum of 106 to 107 CFU/ml was used. Organisms were exposed to drugs for 1 h while incubating at 37°C with shaking at 100 rpm, followed by a 10−4dilution in prewarmed media. One residual antibiotic control containing drugs at 10−4 dilutions of the ELF test concentrations for each of the tested agents was also included in each experiment. Viability counts were performed at the time of drug removal (T0) and at 1-h intervals until cultures reached marked turbidity. PAEs were quantified as previously described (8).

Broth microdilution MICs and MBCs for clarithromycin and azithromycin are presented in Table 1. Mean MICs of clarithromycin and azithromycin for H. influenzae were 3.6 and 0.7 μg/ml, respectively; those for S. pneumoniae were 0.03 and 0.09 μg/ml, respectively.

View this table:
  • View inline
  • View popup
Table 1.

Broth microdilution MICs and MBCs for clarithromycin and azithromycin against H. influenzae andS. pneumoniae

Azithromycin at the concentrations found in ELF displayed the most rapid killing effect on all strains of H. influenzae, with ≥99.9% killed within 6 h for four of five strains. 14-Hydroxy-clarithromycin alone showed the poorest activity againstH. influenzae. All agents tested demonstrated statistically similar killing kinetics against S. pneumoniae at the concentrations found in ELF.

Mean PAEs of drugs at the concentrations found in ELF for H. influenzae and S. pneumoniae are presented in Figure 1. Although the PAE of azithromycin against H. influenzae was 83.3% longer than that of clarithromycin, this difference was not statistically significant. Clarithromycin produced a significantly longer PAE against S. pneumoniae than azithromycin (P < 0.05), as did the clarithromycin–14-hydroxy-clarithromycin combination (P < 0.001). Although the addition of 14-hydroxy-clarithromycin to its parent compound prolonged the PAEs of clarithromycin againstH. influenzae and S. pneumoniae by 29.2 and 22.7%, respectively, these changes were not statistically significant. Clarithromycin, 14-hydroxy-clarithromycin, and the combination of the two produced significantly longer PAEs againstS. pneumoniae than against H. influenzae (P < 0.01, P < 0.01, and P < 0.001, respectively). The PAEs of azithromycin against H. influenzae and S. pneumoniaedid not differ significantly.

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

Durations of PAEs against five strains of H. influenzae and S. pneumoniae of clarithromycin (C), azithromycin (A), 14-hydroxy-clarithromycin (14-OH), and the combination of clarithromycin and 14-hydroxy-clarithromycin (C + 14-OH). Bars represent mean durations + standard errors of the mean. ∗, P < 0.01; ∗∗, P < 0.001.

Lung ELF provides a quantifiable site for study of antibiotic tissue concentration effects on lung infection. Clarithromycin and azithromycin concentrations in ELF employed in this experiment exceeded the MICs for the H. influenzae and S. pneumoniae strains studied, clarithromycin concentrations being >8 times and 1,000 times the mean MICs and azithromycin concentrations being >4 times and >33 times mean MICs forH. influenzae and S. pneumoniae, respectively. The significance of these concentrations is substantiated by efficacy and favorable outcomes of azithromycin therapy while concentrations in serum remain below MICs.

Our findings support previous data (28) indicating that the synergistic relationship between clarithromycin and its major metabolite is not improved by high concentrations in pulmonary tissue. Although addition of 14-hydroxy-clarithromycin to clarithromycin resulted in prolongation of the PAE against H. influenzae and S. pneumoniae, it is not clear whether this relatively small increase would result in a clinically significant effect.

Increasing the concentration above the MIC has produced increased durations of PAEs, at times reaching a maximum effect (8). PAEs observed in the present study are comparable to the PAEs of clarithromycin and azithromycin, at concentrations equal to 10 times the MIC, previously reported in the literature (14, 23). These findings suggest that comparable PAEs for clarithromycin and azithromycin exist once a maximum effect is achieved.

In vitro simulation of fluctuating drug concentrations in the in vivo environment continues to be a limitation of studies examining antibiotic activity, such as in vitro PAE determination. Concentrations in ELF exceeded the MICs for both organisms tested; thus, the clinical significance of the PAEs obtained in vitro is questioned. The accuracy of measurements of concentrations in ELF and the role of active metabolites in infection have also been challenged.

Our results have shown that clarithromycin exhibited greater potency and a significantly longer PAE than azithromycin against S. pneumoniae at concentrations found in ELF. Azithromycin demonstrated greater potency, killing, and PAE than clarithromycin against H. influenzaeat concentrations found in ELF. The data presented question the clinical significance of 14-hydroxy-clarithromycin killing, PAE, and synergistic potential with H. influenzae at concentrations found in ELF. This study also indicates that a maximal PAE may exist despite increasing concentrations of drug.

Overall, the activity of clarithromycin and azithromycin at physiological levels against H. influenzae andS. pneumoniae is an important consideration in the design of tissue-directed antimicrobial therapy. Models of localized infection indicate a correlation between adequate concentrations of appropriate antimicrobials in tissue and decreased morbidity and mortality from infection (15). Additional efforts in examining the importance of antimicrobial activity at concentrations found at the site of infection are required for optimum tissue-directed therapeutic decisions and determination of clinical relevance.

ACKNOWLEDGMENTS

This study was supported in part through a grant from Abbott Pharmaceuticals, Abbott Park, North Chicago, Ill.

We thank Amy Arnold for her laboratory assistance.

FOOTNOTES

    • Received 4 May 1998.
    • Returned for modification 27 October 1998.
    • Accepted 19 February 1999.
  • Copyright © 1999 American Society for Microbiology

REFERENCES

  1. 1.↵
    American Thoracic Society Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am. Rev. Respir. Dis. 148 1993 1418 1426
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Amsden G. W.
    Antimicrobial management strategies for patients with community-acquired respiratory tract infections: another view. Curr. Ther. Res. 58 1997 128 140
    OpenUrlCrossRef
  3. 3.↵
    1. Baldwin D. R.,
    2. Wise R.,
    3. Andrews J. M.,
    4. Ashby J. P.,
    5. Honeybourne D.
    Azithromycin concentrations at the sites of pulmonary infection. Eur. Respir. J. 3 1990 886 890
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Baldwin D. R.,
    2. Honeybourne D.,
    3. Wise R.
    Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob. Agents Chemother. 36 1992 1171 1175
    OpenUrlFREE Full Text
  5. 5.↵
    1. Barry A. L.,
    2. Jones R. N.,
    3. Thornsberry C.
    In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268, TE-031), erythromycin, roxithromycin, and clindamycin. Antimicrob. Agents Chemother. 32 1988 752 754
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Conte J. E. Jr.,
    2. Golden J. A.,
    3. Duncan S.,
    4. McKenna E.,
    5. Zurlinden E.
    Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrob. Agents Chemother. 39 1995 334 338
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Conte J. E. Jr.,
    2. Golden J.,
    3. Duncan S.,
    4. McKenna E.,
    5. Lin E.,
    6. Zurlinden E.
    Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects. Antimicrob. Agents Chemother. 40 1996 1617 1622
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Craig W. A.,
    2. Gudmundsson S.
    Postantibiotic effect Antibiotics in laboratory medicine 4th ed. Lorian V. 1996 296 329 The Williams & Wilkins Co. Baltimore, Md
  9. 9.↵
    1. Dabernat H.,
    2. Delmas C.,
    3. Seguy M.,
    4. Fourtillan J. B.,
    5. Girault J.,
    6. Lareng M. B.
    The activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae, determined by in-vitro and serum bactericidal tests. J. Antimicrob. Chemother. 27 (Suppl. A) 1991 19 30
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Donowitz G. R.,
    2. Mandell G. L.
    Acute pneumonia Principles and practice of infectious diseases 4th ed. Mandell G. L., Bennett J. E., Dolin R. 1995 619 637 Churchill Livingstone Inc. New York, N.Y
  11. 11.↵
    1. Fernandes P. B.,
    2. Bailer R.,
    3. Swanson R.,
    4. Hanson C. W.,
    5. McDonald E.,
    6. Ramer N.,
    7. Hardy D.,
    8. Shipkowitz N.,
    9. Bower R. R.,
    10. Gade E.
    In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob. Agents Chemother. 30 1986 865 873
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Fish D. N.,
    2. Gotfried M. H.,
    3. Danziger L. H.,
    4. Rodvold K. A.
    Penetration of clarithromycin into lung tissues from patients undergoing lung resection. Antimicrob. Agents Chemother. 38 1994 876 878
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Foulds G.,
    2. Shepard R. M.,
    3. Johnson R. B.
    The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. 25 (Suppl. A) 1990 73 82
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Fuursted K.,
    2. Knudsen J. D.,
    3. Petersen M. B.,
    4. Poulsen R. L.,
    5. Rehm D.
    Comparative study of bactericidal activities, postantibiotic effects, and effects on bacterial virulence of penicillin G and six macrolides against Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41 1997 781 784
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Girard A. E.,
    2. Girard D.,
    3. Retsema J. A.
    Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection. J. Antimicrob. Chemother. 25 (Suppl. A) 1990 61 71
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Gu J.,
    2. Scully B. E.,
    3. Neu H. C.
    Bactericidal activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae and streptococcal pathogens. J. Clin. Pharmacol. 31 1991 1146 1150
    OpenUrlPubMedWeb of Science
  17. 17.↵
    1. Hardy D. J.,
    2. Hensey D. M.,
    3. Beyer J. M.,
    4. Vojtko C.,
    5. McDonald E. J.,
    6. Fernandes P. B.
    Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob. Agents Chemother. 32 1988 1710 1719
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Hardy D. J.,
    2. Swanson R. N.,
    3. Rode R. A.,
    4. Marsh K.,
    5. Shipkowitz N. L.,
    6. Clement J. J.
    Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob. Agents Chemother. 34 1990 1407 1413
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Honeybourne D.,
    2. Kees F.,
    3. Andrews J. M.,
    4. Baldwin D.,
    5. Wise R.
    The levels of clarithromycin and its 14-hydroxy metabolite in the lung. Eur. Respir. J. 7 1994 1275 1280
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Isenberg H. D.
    Clinical microbiology procedures handbook. 1995 American Society for Microbiology Washington, D.C
  21. 21.↵
    1. Maskell J. P.,
    2. Sefton A. M.,
    3. Williams J. D.
    Comparative in-vitro activity of azithromycin and erythromycin against gram-positive cocci, Haemophilus influenzae and anaerobes. J. Antimicrob. Chemother. 25 (Suppl. A) 1990 19 24
    OpenUrlCrossRefPubMed
  22. 22.↵
    National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. 1997 National Committee for Clinical Laboratory Standards Wayne, Pa
  23. 23.↵
    1. Odenholt-Tornqvist I.,
    2. Löwdin E.,
    3. Cars O.
    Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. Antimicrob. Agents Chemother. 39 1995 221 226
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Olsen K. M.,
    2. San Pedro G. S.,
    3. Gann L. P.,
    4. Gubbins P. O.,
    5. Halinski D. M.,
    6. Campbell G. D. Jr.
    Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob. Agents Chemother. 40 1996 2582 2585
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Patel K. B.,
    2. Xuan D.,
    3. Tessier P. R.,
    4. Russomanno J. H.,
    5. Quintiliani R.,
    6. Nightingale C. H.
    Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob. Agents Chemother. 40 1996 2375 2379
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Retsema J.,
    2. Girard A.,
    3. Schelkly W.,
    4. Manousos M.,
    5. Anderson M.,
    6. Bright G.,
    7. Borovoy R.,
    8. Brennan L.,
    9. Mason R.
    Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob. Agents Chemother. 31 1987 1939 1947
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Rodvold K. A.,
    2. Gotfried M. H.,
    3. Danziger L. H.,
    4. Servi R. J.
    Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob. Agents Chemother. 41 1997 1399 1402
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Walker K. J.,
    2. Larsson A. J.,
    3. Zabinski R. A.,
    4. Rotschafer J. C.
    Evaluation of antimicrobial activities of clarithromycin and 14-hydroxyclarithromycin against three strains of Haemophilus influenzae by using an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 38 1994 2003 2007
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Download PDF
Citation Tools
Antimicrobial Activities and Postantibiotic Effects of Clarithromycin, 14-Hydroxy-Clarithromycin, and Azithromycin in Epithelial Cell Lining Fluid against Clinical Isolates ofHaemophilus influenzae and Streptococcus pneumoniae
Kimberly L. Bergman, Keith M. Olsen, Tom E. Peddicord, Paul D. Fey, Mark E. Rupp
Antimicrobial Agents and Chemotherapy May 1999, 43 (5) 1291-1293; DOI: 10.1128/AAC.43.5.1291

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Antimicrobial Activities and Postantibiotic Effects of Clarithromycin, 14-Hydroxy-Clarithromycin, and Azithromycin in Epithelial Cell Lining Fluid against Clinical Isolates ofHaemophilus influenzae and Streptococcus pneumoniae
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Antimicrobial Activities and Postantibiotic Effects of Clarithromycin, 14-Hydroxy-Clarithromycin, and Azithromycin in Epithelial Cell Lining Fluid against Clinical Isolates ofHaemophilus influenzae and Streptococcus pneumoniae
Kimberly L. Bergman, Keith M. Olsen, Tom E. Peddicord, Paul D. Fey, Mark E. Rupp
Antimicrobial Agents and Chemotherapy May 1999, 43 (5) 1291-1293; DOI: 10.1128/AAC.43.5.1291
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Anti-Bacterial Agents
azithromycin
clarithromycin
Haemophilus influenzae
Streptococcus pneumoniae

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596